89Bio’s NASH Hopes Hang On Demonstrating Best-In-Class FGF21 Profile

 
• By Joseph Haas
  
competition
89Bio cites multiple reasons why its FGF21 analog for NASH might be best in class
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Strategy

More from Business